1. SARS-CoV-2 Seropositivity and Seroconversion in Patients Undergoing Active Cancer-Directed Therapy
- Author
-
Robert H. Vonderheide, Jasmin Hussain, Madeline L Good, Scott M. Dudek, Lova Sun, Shefali S. Verma, Daniel J. Rader, Heena Desai, Angela DeMichele, Robert E. Gross, Shannon DeLuca, Kara N. Maxwell, Christopher M McAllister, Stacy Pundock, Madison E. Weirick, Cathy Zheng, Gregory Kelly, Lisa A. Varughese, AnnaClaire Osei-Akoto, Yolanda R Kry, Ronac Mamtani, Ivan Maillard, Sanjna Surya, Erin Bange, Anh N Le, Sigrid Gouma, Lynn M. Schuchter, Emily M. Kugler, Seth Jeffries, E. Paul Wileyto, Noah Goodman, JoEllen Weaver, Olutosin Owoyemi, Abigail Doucette, Timothy Prior, Maikel Mansour, Marylyn D. Ritchie, Scott E. Hensley, Peter Gabriel, John Ndicu, Anurag Verma, and Alexander C. Huang
- Subjects
2019-20 coronavirus outbreak ,Longitudinal study ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,ORIGINAL CONTRIBUTIONS ,Article ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Neoplasms ,Health care ,Pandemic ,medicine ,Humans ,In patient ,Longitudinal Studies ,Seroconversion ,Pandemics ,030304 developmental biology ,0303 health sciences ,biology ,Oncology (nursing) ,Transmission (medicine) ,business.industry ,SARS-CoV-2 ,Health Policy ,Cancer ,COVID-19 ,medicine.disease ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Antibody ,business - Abstract
PURPOSE:Multiple studies have demonstrated the negative impact of cancer care delays during the COVID-19 pandemic, and transmission mitigation techniques are imperative for continued cancer care delivery. We aimed to gauge the effectiveness of these measures at the University of Pennsylvania.METHODS:We conducted a longitudinal study of SARS-CoV-2 antibody seropositivity and seroconversion in patients presenting to infusion centers for cancer-directed therapy between May 21, 2020, and October 8, 2020. Participants completed questionnaires and had up to five serial blood collections.RESULTS:Of 124 enrolled patients, only two (1.6%) had detectable SARS-CoV-2 antibodies on initial blood draw, and no initially seronegative patients developed newly detectable antibodies on subsequent blood draw(s), corresponding to a seroconversion rate of 0% (95% CI, 0.0 TO 4.1%) over 14.8 person-years of follow up, with a median of 13 health care visits per patient.CONCLUSION:These results suggest that patients with cancer receiving in-person care at a facility with aggressive mitigation efforts have an extremely low likelihood of COVID-19 infection.
- Published
- 2021